Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Parthika Patel

M. Pharm (Pharmaceutics)

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Home

Parthika Patel

Articles By : Parthika Patel

NPPA Warns Drugmakers Against Arbitrary Pricing, Calls for MRP Uniformity

Parthika Patel26 July 2025 10:52 PM IST

New Delhi: In a move to ensure uniform pricing and check arbitrary price differences across pharmaceutical brands, the National Pharmaceutical Pricing...

NPPA Committee Asks Intas to Clarify Patent Discrepancy in Clozapine ER Pricing Plea

Parthika Patel26 July 2025 8:47 PM IST

New Delhi: The Multidisciplinary Committee (MDC) of Experts under the National Pharmaceutical Pricing Authority (NPPA) has asked Intas Pharmaceuticals...

CDSCO Panel Seeks Safety Data on 5% Lenalidomide TDS Before Clearing 8% Patch Trial

Parthika Patel25 July 2025 4:38 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has not granted...

CDSCO Panel Approves Phase IV Protocol Amendment for Bristol-Myers Squibb's Mavacamten Study

Parthika Patel24 July 2025 6:49 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has...

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC

Eris Gets CDSCO Panel Nod To Dapagliflozin-Bisoprolol-Sacubitril Valsartan Combo Kit, Phase IV Trial Mandated

Parthika Patel23 July 2025 7:41 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has...

Zydus Secures CDSCO Panel Go-Ahead For Phase III Trial of Empagliflozin-Metoprolol FDC

Parthika Patel22 July 2025 6:19 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has...

CDSCO Flags MSD Pharmas Cancer Drug Trial Over Indian Representation, Control Arm

CDSCO Panel Nod To MSD's Sotatercept Label Change, Expands Prescribing Rights to Cardiologists

Parthika Patel21 July 2025 10:32 PM IST

New Delhi: The Subject Expert Committee (SEC) under Central Drugs Standard Control Organisation's (CDSCO) Cardiovascular division has approved MSD...

AstraZeneca Koselugo recommended for approval in EU for plexiform neurofibromas in adults with neurofibromatosis type 1

CDSCO Panel Clears AstraZeneca's Datopotamab for Breast Cancer, Seeks Phase IV Trial

Parthika Patel20 July 2025 1:03 AM IST

New Delhi: The Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has granted...

Expert Drug Panel Clears Proposal to Amend Licensing Forms for Advanced Biologics, Xenografts

Parthika Patel16 July 2025 4:15 PM IST

New Delhi: The apex advisory body functioning under the Central Drugs Standard Control Organisation (CDSCO), Drugs Consultative Committee (DCC),...

Zydus Gets SEC Nod to Begin Phase IV Trial of Dydrogesterone ER for Habitual Miscarriage

Parthika Patel15 July 2025 8:21 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Reproductive division of the Central Drugs Standard Control Organisation (CDSCO) has granted...

CDSCO Panel Approves GSK's Proposal to Double Indian Patient Pool in Dostarlimab Trial

Parthika Patel15 July 2025 7:34 PM IST

New Delhi: In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control...

Child Given Wrong Injection at Government Hospital

SEC Flags Safety, Efficacy Gaps in Troikaa's Rapid IV Paracetamol Bolus Proposal, Seeks More Data

Parthika Patel12 July 2025 7:59 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has declined to approve Troikaa...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok